<?xml version='1.0' encoding='utf-8'?>
<document id="29101463"><sentence text="A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors."><entity charOffset="75-86" id="DDI-PubMed.29101463.s1.e0" text="fluvoxamine" /><entity charOffset="114-123" id="DDI-PubMed.29101463.s1.e1" text="dovitinib" /><pair ddi="false" e1="DDI-PubMed.29101463.s1.e0" e2="DDI-PubMed.29101463.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29101463.s1.e0" e2="DDI-PubMed.29101463.s1.e1" /></sentence><sentence text="Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1-3, FGFR 1-3, and PDGFR"><entity charOffset="0-9" id="DDI-PubMed.29101463.s2.e0" text="Dovitinib" /><entity charOffset="39-47" id="DDI-PubMed.29101463.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.29101463.s2.e0" e2="DDI-PubMed.29101463.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29101463.s2.e0" e2="DDI-PubMed.29101463.s2.e1" /></sentence><sentence text=" This study was performed to investigate the potential drug-drug interaction of dovitinib with the CYP1A2 inhibitor fluvoxamine in patients with advanced solid tumors"><entity charOffset="116-127" id="DDI-PubMed.29101463.s3.e0" text="fluvoxamine" /></sentence><sentence text="" /><sentence text="Non-smoking patients of ≥ 18 years with advanced solid tumors, excluding breast cancer, were included" /><sentence text=" Patients were treated with a dose of 300 mg in 5 days on/2 days off schedule" /><sentence text=" Steady-state pharmacokinetic assessments of dovitinib were performed with or without fluvoxamine"><entity charOffset="45-54" id="DDI-PubMed.29101463.s7.e0" text="dovitinib" /><entity charOffset="86-97" id="DDI-PubMed.29101463.s7.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.29101463.s7.e0" e2="DDI-PubMed.29101463.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29101463.s7.e0" e2="DDI-PubMed.29101463.s7.e1" /></sentence><sentence text="" /><sentence text="Forty-five patients were enrolled; 24 were evaluable for drug-drug interaction assessment" /><sentence text=" Median age was 60 years (range 30-85)" /><sentence text=" At steady state the geometric mean for dovitinib (coefficient of variation%) of the area under the plasma concentration-time curve (AUC0-72h) and maximum concentration (C max) were 2880 ng/mL h (47%) and 144 ng/mL (41%), respectively" /><sentence text=" Following administration of dovitinib in combination with fluvoxamine the geometric mean of dovitinib AUC0-72h and C max were 8290 ng/mL h (60%) and 259 ng/mL (45%), respectively"><entity charOffset="29-38" id="DDI-PubMed.29101463.s12.e0" text="dovitinib" /><entity charOffset="59-70" id="DDI-PubMed.29101463.s12.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.29101463.s12.e0" e2="DDI-PubMed.29101463.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29101463.s12.e0" e2="DDI-PubMed.29101463.s12.e1" /></sentence><sentence text=" The estimated geometric mean ratios for dovitinib AUC0-72h and C max (dovitinib + fluvoxamine vs" /><sentence text=" dovitinib alone) were 2" /><sentence text="88 [90% confidence interval (CI) 2" /><sentence text="58, 3" /><sentence text="20] and 1" /><sentence text="80 (90% CI 1" /><sentence text="66, 1" /><sentence text="95)" /><sentence text=" This effect is considered a moderate drug-drug interaction" /><sentence text="" /><sentence text="Fluvoxamine co-administration resulted in a 80% increase in C max and a 188% increase in AUC0-72h of dovitinib"><entity charOffset="0-11" id="DDI-PubMed.29101463.s23.e0" text="Fluvoxamine" /></sentence><sentence text=" Given the increase in exposure to dovitinib observed, patients are at risk of dovitinib related toxicity"><entity charOffset="79-88" id="DDI-PubMed.29101463.s24.e0" text="dovitinib" /></sentence><sentence text=" Dovitinib should, therefore, not be co-administered with moderate and strong CYP1A2 inhibitors, without dose reduction"><entity charOffset="1-10" id="DDI-PubMed.29101463.s25.e0" text="Dovitinib" /></sentence><sentence text="" /></document>